

Jeffrey M Trent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7268419/publications.pdf>

Version: 2024-02-01

24
papers

3,094
citations

430874

18
h-index

610901

24
g-index

26
all docs

26
docs citations

26
times ranked

4873
citing authors

#	ARTICLE	IF	CITATIONS
1	High frequency of BRAF mutations in nevi. <i>Nature Genetics</i> , 2003, 33, 19-20.	21.4	1,547
2	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. <i>Nature Genetics</i> , 2014, 46, 427-429.	21.4	298
3	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. <i>Nature Genetics</i> , 2012, 44, 165-169.	21.4	170
4	Dual loss of the SWI/SNF complex ATPases SMARCA4 and BRG1 and SMARCA2 and BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2016, 238, 389-400.	4.5	169
5	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. <i>Clinical Cancer Research</i> , 2014, 20, 4200-4209.	7.0	127
6	Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. <i>Genome Research</i> , 2017, 27, 524-532.	5.5	122
7	Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. <i>Science Translational Medicine</i> , 2016, 8, 324ps5.	12.4	108
8	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. <i>Gynecologic Oncology</i> , 2016, 141, 454-460.	1.4	85
9	The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2017, 242, 371-383.	4.5	78
10	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. <i>PLoS Genetics</i> , 2018, 14, e1007589.	3.5	56
11	Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. <i>Clinical Cancer Research</i> , 2018, 24, 1932-1943.	7.0	51
12	Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2767-2779.	4.1	50
13	Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). <i>Rare Diseases (Austin, Tex)</i> , 2014, 2, e967148.	1.8	40
14	Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing. <i>Nature Biotechnology</i> , 2021, 39, 1151-1160.	17.5	39
15	Prospective Molecular Profiling of Canine Cancers Provides a Clinically Relevant Comparative Model for Evaluating Personalized Medicine (PMed) Trials. <i>PLoS ONE</i> , 2014, 9, e90028.	2.5	33
16	Feasibility of implementing molecularly-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. <i>Cancer Medicine</i> , 2015, 4, 871-886.	2.8	26
17	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1962-1971.	4.1	25
18	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , 2020, 26, 4402-4413.	7.0	21

#	ARTICLE	IF	CITATIONS
19	HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases. <i>Cancer Research</i> , 2020, 80, 3009-3022.	0.9	19
20	Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. <i>Cancer Research</i> , 2021, 81, 5818-5832.	0.9	10
21	The Gene Topography of Cancer. <i>Science</i> , 2007, 318, 1079-1080.	12.6	5
22	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. <i>PLoS ONE</i> , 2021, 16, e0248097.	2.5	5
23	A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma. <i>Cancer Reports</i> , 2022, 5, e1616.	1.4	5
24	The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series. <i>Oncotarget</i> , 2021, 12, 1836-1847.	1.8	1